POLITICS

GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports

PUBLISHED Sep 13, 2026, 1:07 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 44

Left 9%

Center 86%

Right 5%

Sources: 44

GE HealthCare Technologies is reportedly engaged in late-stage negotiations to acquire radiopharmaceutical developer Sofie Biosciences for approximately $1 billion. According to individuals familiar with the matter cited by financial media reports, a formal agreement could be announced as early as next week. Neither company has officially confirmed the discussions, and corporate representatives declined to comment outside regular business hours. If finalized, the transaction would represent GE HealthCare's second major acquisition following its corporate spin-off from General Electric in 2024. The potential purchase is designed to strengthen GE HealthCare's pharmaceutical diagnostics division by expanding its portfolio of radioactive tracers and chemicals utilized in advanced cancer scans and targeted radiotherapy. Market analysts note that the acquisition would position the medical technology firm more competitively within the rapidly growing global radiopharmaceutical sector, where major healthcare corporations are aggressively consolidating specialized assets to capture rising demand for molecular imaging and precision oncology treatments.

By Sidra | JQJO News

Timeline of Events

On January 4 2024 GE HealthCare completed its corporate separation from General Electric.
On September 13 2026 Financial Times reported potential acquisition talks between companies.
On September 13 2026 Reuters published details regarding estimated billion dollar valuation.
On September 14 2026 market observers awaited official corporate announcements regarding potential transaction.
On September 15 2026 industry specialists analyzed strategic healthcare portfolio integration prospects.
On September 16 2026 investors monitored regulatory compliance indicators for radiopharmaceutical sector expansion.
On September 17 2026 corporate governance teams reviewed potential asset consolidation financial impacts.
On September 18 2026 financial analysts assessed valuation metrics for targeted molecular imaging developers.
On September 19 2026 market participants evaluated competitive dynamics across medical diagnostic divisions.
On September 20 2026 stakeholders anticipated forthcoming official statements regarding negotiation outcomes.

News Intelligence

Immediate US impact: Expands domestic access to advanced cancer diagnostic imaging agents nationwide.
Possible long-term US impact: Strengthens US leadership in precision radiopharmaceutical manufacturing and research capabilities.
Most affected groups: United States oncology patients, medical imaging technicians, and healthcare investors.
Reader priority: Verify corporate announcements across financial news networks and investor relations portals.

Media Bias

Articles Published:: 44
Right Leaning:: 2
Left Leaning:: 4
Neutral:: 38

Explain Framing

Left: Emphasizes corporate consolidation impacts on healthcare access and pricing. Center: Reports financial terms and strategic corporate expansion details neutrally. Right: Highlights capital investment efficiency and post-spinoff market growth strategies.